RxDoctor Payments Data

Arnold Lee, NP

Family · Chandler, AZNPI 1770118937

Payments from drug & device makers

$4,735in general payments, 2019–2025

Across 132 payments — averaging $35.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • Novo Nordisk$509
  • Johnson & Johnson$419
  • Biotronik Inc.$296
  • Heartflow, Inc.$243
  • AstraZeneca$234
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$1,00521%
  • Food & beverage$3,59676%
  • Education$1343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,735 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$2,171
Medicare patients
19
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$99,082
XareltoRivaroxaban36$34,261
EntrestoSacubitril/Valsartan22$28,859
Metoprolol Succinate182$2,439
Losartan Potassium150$1,650
Ranolazine ErRanolazine14$1,584
Lisinopril169$1,447
Atorvastatin Calcium94$1,068
Amlodipine Besylate126$991
Nebivolol Hcl13$927
Flecainide Acetate17$795
Hydralazine Hcl70$659
Valsartan14$609
Isosorbide Mononitrate ErIsosorbide Mononitrate58$607
Cilostazol11$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$99,08272 claims
Johnson & JohnsonXarelto$419$34,26136 claims
NovartisEntresto$116$28,85922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →